Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of WS016 in Patients With Hyperkalemia

NCT07251309 is registered in ClinicalTrials.gov with Waterstone Pharmaceutical (Wuhan) Co., LTD. as lead sponsor.

NCT NCT07251309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07251309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of WS016 in Patients With Hyperkalemia
Lead sponsor
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase
Phase 3
Overall status
Recruiting
Start date
December 23, 2024
Completion date
November 30, 2026
Enrollment
420 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia